Novel Model Aids Prediction of Survival in Heart Failure With Reduced Ejection Fraction
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 25, 2023 -- For individuals with heart failure with reduced ejection fraction (HFrEF), a new model facilitates prediction of lifelong overall and heart failure hospitalization-free survival and treatment benefit, according to a study published online Sept. 10 in the European Journal of Heart Failure.
Pascal M. Burger, from the University Medical Centre Utrecht in the Netherlands, and colleagues developed and validated the LIFEtime-perspective for Heart Failure (LIFE-HF) model for predicting lifetime risk and treatment benefit in patients with HFrEF. The model was developed in 15,415 participants from the PARADIGM-HF and ATMOSPHERE trials. External validation was performed in 51,286 participants in the SwedeHF registry, ASIAN-HF registry, and DAPA-HF trial.
The researchers found adequate calibration of two- to 10-year risk, and the c-statistics were 0.65 to 0.74, respectively. The model was combined with hazard ratios from trials to allow estimation of an individual's (lifetime) risk and treatment benefit. Combined treatment with a mineralocorticoid receptor antagonist, sodium-glucose cotransporter 2 inhibitor, and angiotensin receptor-neprilysin inhibitor was estimated to afford a median of 2.5 and 3.7 additional years of overall and heart failure hospitalization-free survival, respectively, by applying the tool to the development cohort.
"The model could serve as a tool to improve the management of patients with HFrEF by facilitating personalized medicine and shared decision-making," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Sociodemographics Tied to Rehab Use During Critical Illness Hospitalization
FRIDAY, May 10, 2024 -- For older adults hospitalized with a stay in the intensive care unit (ICU), social determinants of health (SDOH) are associated with use of skilled...
Breakthrough Gene Therapy Enables Infant Born Deaf to Hear
FRIDAY, May 10, 2024 -- Significant hearing improvements have been achieved in an infant with profound hearing loss due to a biallelic otoferlin gene (OTOF) mutation, according to...
Implantable Continuous Flow Device Feasible for Small Children With Severe Systolic Heart Failure
FRIDAY, May 10, 2024 -- The Jarvik 2015 left ventricular assist device (LVAD) seems promising as an implantable continuous flow device for small children with severe systolic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.